Monitor your assay performance and avoid the possibility of false positives and negatives with characterized controls at precise allelic frequencies
Highly characterized human cell lines that use CRISPR-Cas9 gene-editing to disable genes of interest. Over 4000 gene targets represented in our ready to ship catalogue.
The fastest custom generation service, with design to delivery capabilities. Off the shelf KO models available including exclusive optogenetics. Expanding range of high fidelity PDX models.
Our expertise comes from over 4000 gene modifications completed across many cell types. We apply this core capability to deliver innovative scientific solutions; across functional & translations genomics, drug discovery and development.
Combined with IP coverage, our experience across gene editing technologies means we have an agnostic approach.
rAAV uses an exchange of nucleotide sequences to enable insertion, deletion or replacement of DNA sequences in cells. Unlike other methods this is achieved without causing a double strand DNA break.
rAAV can be over 1,000 times more efficient at gene-targeting than plasmid-based methods and is an excellent tool for the generation of knockins, or any modifications that should involve a single allele.
ZFNs are engineered DNA binding proteins that can be designed to bind to a variety of DNA sequences by introducing a double stranded break at a specified location in the genome. This technique is particularly effective at knocking out gene function.
This technology is licensed for use in custom in vivo gene-editing projects.
Transposons are segments of chromosome that can be transposed to a new location within the DNA of a host cell. Transposon mutagenesis, or transposition mutagenesis, is a biological process that interrupts or changes cell DNA causing loss or gain of gene function or mutation.
This technique has been adapted for use in the laboratory as a method of gene editing.
We work with the world’s leading academic institutes and top pharmaceutical companies; proudly serving thousands of genomic and translational researchers.